Daclatasvir (brand name Daklinza) is a prescription medication used in combination with other medications to treat chronic (long-lasting) hepatitis C virus (HCV) infection in adults. It is a type of antiviral medication that works by blocking the action of a viral protein called NS5A, which is important for the virus to replicate and survive in the body. Typically, it is used in combination with sofosbuvir and is taken once daily as a single pill.
Daclatasvir, previously sold under the brand name Daklinza, was an antiviral medication used in combination with other medications to treat chronic Hepatitis C infection [1, 2]. It's important to note that Daclatasvir is no longer widely prescribed due to the development of more effective treatment options [2].
Here's a breakdown of what Daclatasvir was used for:
- Treatment of chronic Hepatitis C: Daclatasvir, in combination with other antivirals like sofosbuvir, helped to combat the Hepatitis C virus (HCV) and reduce its replication in the body [1, 2].
- Specific genotypes: Daclatasvir was primarily effective against genotypes 1 and 3 of the Hepatitis C virus [2].
How it worked:
- Daclatasvir belongs to a class of drugs called direct-acting antiviral agents (DAAs) that target specific stages in the HCV replication process [2].
- Specifically, Daclatasvir inhibits the NS5A region of the HCV, which is essential for viral replication [2]. By blocking this process, it helped to reduce the viral load and potentially clear the infection from the body.
Important to know:
- Daclatasvir was never meant to be used alone and was always prescribed in combination with other antiviral medications for Hepatitis C treatment [1].
- Due to the availability of more potent DAAs with simpler treatment regimens and fewer side effects, Daclatasvir has been largely superseded for Hepatitis C treatment [2].
If you have Hepatitis C:
- If you are considering treatment for Hepatitis C, it's important to consult with a healthcare professional. They can determine the most appropriate treatment regimen based on your specific case and the latest recommendations.